Octapharma USA's Kerem Tokel explains how tariffs and DSCSA are affecting how stolen pharma loads are resold, and why partner SOPs matter.
|Articles|November 6, 2013
- Pharmaceutical Commerce - November/December 2013
Commercial Data Sources for the Biopharma Industry
Advertisement
Click the link below to view the online, digital version:
Articles in this issue
almost 13 years ago
Academics lay into drug coupon programs in NEJM:almost 13 years ago
HDMA leadership remains with David Neu of AmerisourceBergenalmost 13 years ago
FedEx, IAG Cargo unveil new cold-chain capabilitiesalmost 13 years ago
A conversation with Michael Swanick, PwCalmost 13 years ago
DME competitive bidding issues: When is enough enough?Advertisement
Related to this article
Liberty Dewey of Cardinal Health breaks down the NDC-12 transition timeline, the four work streams driving it and why the biggest risk sits in trading partner handoffs.
At LogiPharma USA 2026, Cold Chain Technologies' TJ Rizzo explains how gaps in end-to-end cold chain expertise create risk for advanced therapies.
At LogiPharma USA 2026, Mark Talens explains where pharma gains the most from shared distribution visibility.
In this week's Pharma Pulse, PhRMA sues to block CMS's GLOBE pricing model, WFS opens a temperature-controlled cargo terminal in Lyon and Bayer commits $2.2 billion to a new Ohio manufacturing site.
Freehand CEO Nitin Jayakrishnan explains why pharma manufacturers are trading long-term plans for operating models built to sense and pivot.
PhRMA's lawsuit argues CMS overstepped its demonstration authority by tying Medicare Part B rebates to international prices.
At LogiPharma USA 2026, Swisslog's Garrett Freeman explains how onshoring, geopolitical risk and a shifting product mix are driving supply chain automation.
Advertisement
Advertisement
Trending on Pharmaceutical Commerce
1
Why Securing Pharma Freight Starts With Broker and Carrier SOPs
2
Supply Chain Visibility Needs Context Before AI, Says PAXAFE’s Mark Talens
3
LogiPharma USA 2026: Where Cold Chain Expertise Gaps Become Product Risk
4
Pharma Pulse: PhRMA Sues to Block GLOBE Model and Bayer's $2.2B Ohio Site
5